CHRS — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-05

• Comparison of Three and Six Months Ended June 30, 2026 and 2025

• The increases in LOQTORZI net revenue for the three and six months ended June 30, 2026, compared to the same periods in the prior year, were driven primarily by volume growth of LOQTORZI.

• The reduction in internal costs for the three months ended June 30, 2026 includes a $2.3 million decrease in employee-related costs including stock-based compensation. The reduction in internal costs for the six months ended June 30, 2026 includes a $3.5 million decrease in employee-related costs, i…

• We expect our fixed research and development expenses in 2026 to be lower than in 2025 primarily due to lower expenditures on manufacturing-related development activities and reduced headcount.

• We expect interest expense from continuing operations to be comparable in 2026 to 2025.

Text removed vs the prior filing · source: 10-Q · 2026-05-11

• The increase in LOQTORZI net revenue for the three months ended March 31, 2026 compared to the same period in the prior year was driven primarily by volume growth of LOQTORZI.

• See above table. Casdozokitug and tagmokitug are our two pipeline product candidates with on-going clinical trials. The reduction in internal costs includes a $1.9 million decrease in facilities, supplies, material and other infrastructure costs and a $1.1 million decrease in stock-based compensatio…

• We expect our fixed research and development expenses in 2026 to be lower than in 2025 primarily due to lower expenditures on manufacturing-related development activities and reduced headcount. Total overall research and development expenses, which includes external clinical costs, will be a functio…

• We expect interest expense from continuing operations to be slightly lower in 2026 than 2025, primarily as a result of the downward trend in market interest rates relative to the 2025 period.

• The reduction in net loss from discontinued operations was primarily driven by a reduction in UDENYCA Business given the UDENYCA Sale occurred April 11, 2025. Favorable items included lower cost of goods sold of $19.3 million, lower selling, general and administrative expense of $7.1 million, lower …

Text removed vs the prior filing · source: 10-Q · 2026-05-11

• We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and in Item 10(f)(1) of Regulation S-K, therefore this disclosure item is not applicable.

Text added vs the prior filing · source: 10-Q · 2026-08-05

• For example, as of June 30, 2026, we had an accumulated deficit of $1.4 billion. The losses and accumulated deficit were primarily due to the substantial investments we made to commercialize our product and identify, develop or acquire our product candidates, including conducting, among other things…

• We have incurred and anticipate we will continue to incur certain development and commercial expenses for LOQTORZI, the anti-PD-1 antibody we licensed from Junshi Biosciences in 2021, and we have agreed to pay up to $90.0 million for the achievement of certain regulatory approvals and up to $290.0 m…

• physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are unable to successfully complete development and obtain additional regulatory approval for our product, our business may suffer.

• The commercial success of our existing product or any future products will depend upon the size of the applicable markets and the degree of market acceptance and adoption by prescribing physicians, healthcare providers and the patients to whom our medicines are prescribed. Additionally, obtaining pl…

• outside the United States, the reimbursement for our product may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.

Text removed vs the prior filing · source: 10-Q · 2026-05-11

• approval. Innovative oncology product development is a highly speculative undertaking and involves a substantial degree of risk.

• For example, as of March 31, 2026, we had an accumulated deficit of $1.4 billion. The losses and accumulated deficit were primarily due to the substantial investments we made to commercialize our product and identify, develop or acquire our product candidates, including conducting, among other thing…

• We have incurred and anticipate we will continue to incur certain development and commercial expenses for LOQTORZI, the anti-PD-1 antibody we licensed from Junshi Biosciences in 2021, and have agreed to pay up to $90.0 million for the achievement of certain regulatory approvals and up to $290.0 mill…

• The commercial success of our existing product or any future products will depend upon the size of the applicable markets and the degree of market acceptance and adoption by prescribing physicians, healthcare providers and the

• patients to whom our medicines are prescribed. Additionally, obtaining placement on national or local clinical guidelines/pathways, as well as coverage on third-party payor formularies, can impact our short and long-term financial performance.